Dapagliflozin (Farxiga): Half-Life and Label | Dose Track
[Prescription · Compound guide]

Dapagliflozin: half-life, strengths and approval status

Tablet strengths · Approval status · Half-life ~12.9 hours

Short answer: Dapagliflozin has a half-life of about 12.9 hours. Levels peak within 2 hours after a dose. People vary, so treat these as estimates.

What is dapagliflozin?

Dapagliflozin is an SGLT2 inhibitor: it makes the kidneys pass more sugar into the urine. It is sold as Farxiga, a once-daily tablet approved for chronic kidney disease, heart failure and type 2 diabetes.

Also known as: Farxiga.

Tablet strengths

Farxiga comes as 5 mg and 10 mg tablets.

Approval status and how it is used

The FDA Farxiga label approves it to slow kidney decline in adults with chronic kidney disease; to lower the risk of heart-related death and heart failure hospital stays in adults with heart failure; to lower heart failure hospital stays in adults with type 2 diabetes and heart disease or risk factors; and, with diet and exercise, to improve blood sugar in adults and children 10 and older with type 2 diabetes. For blood sugar the label starts at 5 mg once a day and may go to 10 mg; for the other uses it is 10 mg once a day. It is not for blood sugar control in type 1 diabetes, or for blood sugar when eGFR is below 45.

Like other SGLT2 inhibitors, its first listed serious risk is ketoacidosis, which can happen with near-normal blood sugar; the label says to stop it at least 3 days before surgery or long fasting if possible. It can also cause dehydration, genital yeast infections and urinary infections. See the Farxiga side effects and missed dose pages.

Dapagliflozin half-life and time to peak

  • Half-lifeabout 12.9 hours
  • Time to peak (Tmax)within 2 hours

The FDA Farxiga label gives a mean terminal half-life of about 12.9 hours after a single 10 mg dose and peak levels usually within 2 hours when fasting. Bioavailability of a 10 mg dose is 78%. A high-fat meal lowers the peak by up to 50% and delays it by about 1 hour, but the label says it can be taken with or without food.

Numbers shown are taken from the source above. Half-life varies from person to person.

How to track dapagliflozin in Dose Track

  1. Add dapagliflozin as a custom compound. Start typing its name and Dose Track fills in the details from its research library for you to check, and it sits next to everything else you take.
  2. Log each tablet when you take it, including split or fractional tablets, so your history shows exactly what you took and when.
  3. Set reminders on your own schedule, whether that is daily, weekly or every few days.
  4. Your log is stored on your phone and no account is needed. Data only leaves it for features you choose, like AI answers and lab reading.

How Dose Track handles peptides · Reconstitution calculator · Half-life calculator

Frequently asked questions

What is the half-life of dapagliflozin?+
The FDA Farxiga label gives a mean terminal half-life of about 12.9 hours after a single 10 mg dose and peak levels usually within 2 hours when fasting. Bioavailability of a 10 mg dose is 78%. A high-fat meal lowers the peak by up to 50% and delays it by about 1 hour, but the label says it can be taken with or without food.
What is the difference between Farxiga and Jardiance?+
Both are once-daily SGLT2 inhibitors. Farxiga (dapagliflozin) comes in 5 and 10 mg tablets and has a label half-life of about 12.9 hours; Jardiance (empagliflozin) comes in 10 and 25 mg tablets with a half-life of about 12.4 hours. Their approved uses overlap but are worded differently on each label.
Can I track dapagliflozin in Dose Track?+
Yes. Dapagliflozin is in Dose Track's research library, so when you add it as a custom compound its details are filled in for you to check. You can then log each tablet next to your other compounds, set reminders on your own schedule, and see your history next to your lab results. Your log is stored on your phone and no account is needed. Data only leaves it for features you choose, like AI answers and lab reading.